Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision
On the basis of multicriteria analysis, a pilot complex system for evaluating medicinal products (MP) used in the therapy of oncohematological diseases has been developed. The obtained results allow to rank MPs by priority of choice when making decisions on procurement of drugs or inclusion in MP li...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Izdatelstvo OKI
2018-07-01
|
| Series: | Качественная клиническая практика |
| Subjects: | |
| Online Access: | https://www.clinvest.ru/jour/article/view/400 |
| id |
doaj-9a3b4a8d998943f1820089a9ec0b3dc2 |
|---|---|
| record_format |
Article |
| spelling |
doaj-9a3b4a8d998943f1820089a9ec0b3dc22020-11-25T02:54:40ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732018-07-010241110.24411/2588-0519-2018-10040403Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provisionS. V. Nedogoda0A. S. Salasyuk1I. N. Barykina2V. O. Smirnova3E. A. Popova4FGBOU VO "Volgograd State Medical University", Russia, VolgogradFGBOU VO "Volgograd State Medical University", Russia, VolgogradFGBOU VO "Volgograd State Medical University", Russia, VolgogradFGBOU VO "Volgograd State Medical University", Russia, VolgogradFGBOU VO "Volgograd State Medical University", Russia, VolgogradOn the basis of multicriteria analysis, a pilot complex system for evaluating medicinal products (MP) used in the therapy of oncohematological diseases has been developed. The obtained results allow to rank MPs by priority of choice when making decisions on procurement of drugs or inclusion in MP lists in the framework of programs of preferential drug provision of the population. It has been shown that, according to the set of criteria, ibrutinib in treatment of chronic lymphocytic leukemia (CLL) has the highest priority, followed by obinutuzumab (CLL treatment) and ruxolitinib (treatment of myelofibrosis).https://www.clinvest.ru/jour/article/view/400multicriteria analysisdrug provisiononcohematologyhealth technology assessmentibrutinib: obinutuzumabruxolitinib |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova E. A. Popova |
| spellingShingle |
S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova E. A. Popova Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision Качественная клиническая практика multicriteria analysis drug provision oncohematology health technology assessment ibrutinib: obinutuzumab ruxolitinib |
| author_facet |
S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova E. A. Popova |
| author_sort |
S. V. Nedogoda |
| title |
Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision |
| title_short |
Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision |
| title_full |
Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision |
| title_fullStr |
Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision |
| title_full_unstemmed |
Multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision |
| title_sort |
multicriteria analysis of the assortment of innovative drugs in oncohematology as a tool for supporting decision-making in the field of drug provision |
| publisher |
Izdatelstvo OKI |
| series |
Качественная клиническая практика |
| issn |
2588-0519 2618-8473 |
| publishDate |
2018-07-01 |
| description |
On the basis of multicriteria analysis, a pilot complex system for evaluating medicinal products (MP) used in the therapy of oncohematological diseases has been developed. The obtained results allow to rank MPs by priority of choice when making decisions on procurement of drugs or inclusion in MP lists in the framework of programs of preferential drug provision of the population. It has been shown that, according to the set of criteria, ibrutinib in treatment of chronic lymphocytic leukemia (CLL) has the highest priority, followed by obinutuzumab (CLL treatment) and ruxolitinib (treatment of myelofibrosis). |
| topic |
multicriteria analysis drug provision oncohematology health technology assessment ibrutinib: obinutuzumab ruxolitinib |
| url |
https://www.clinvest.ru/jour/article/view/400 |
| work_keys_str_mv |
AT svnedogoda multicriteriaanalysisoftheassortmentofinnovativedrugsinoncohematologyasatoolforsupportingdecisionmakinginthefieldofdrugprovision AT assalasyuk multicriteriaanalysisoftheassortmentofinnovativedrugsinoncohematologyasatoolforsupportingdecisionmakinginthefieldofdrugprovision AT inbarykina multicriteriaanalysisoftheassortmentofinnovativedrugsinoncohematologyasatoolforsupportingdecisionmakinginthefieldofdrugprovision AT vosmirnova multicriteriaanalysisoftheassortmentofinnovativedrugsinoncohematologyasatoolforsupportingdecisionmakinginthefieldofdrugprovision AT eapopova multicriteriaanalysisoftheassortmentofinnovativedrugsinoncohematologyasatoolforsupportingdecisionmakinginthefieldofdrugprovision |
| _version_ |
1724719651639787520 |